Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic agents and include a broad range of products such as growth factors, hormones, vaccines, monoclonal antibodies, cytokines and few others. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bioreactivity and success rate in treating life-threatening diseases and injuries.

The global Bioengineered Protein Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Bioengineered Protein Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bioengineered Protein Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Bioengineered Protein Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Bioengineered Protein Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbot
Amgen
Baxter
Bayer
Eli Lilly
GlaxoSmithKline
Fresenius Kabi
Hoffman-la-Roche
Johnson & Johnson
Merck

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Recombinant protein drugs
Peptide hormones
Vaccines
Therapeutic enzymes
Monoclonal antibodies
Cytokines
Replacement proteins
Peptide antibiotics
Blood products

Segment by Application
Fractionation
Bioreactors and microbial cell fermentation
Genetic engineering
Genetically modified organisms
Pharming
Bioengineered protein drugs produced by transgenic microorganisms, plants and animals
Cell culture
Others